Onconetix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on September 22, 2025, and September 24, 2025, with the report filed on September 26, 2025. Onconetix, Inc. (ONCO), a Delaware corporation and emerging growth company, announced a private investment in public equity (PIPE) financing, a settlement of outstanding debt with Veru Inc., and the termination of a previously announced merger agreement with Ocuvex Therapeutics, Inc.
Key Financial Metrics and Capital Structure
- PIPE Financing Proceeds: Aggregate purchase price of approximately $12.9 million.
- Cash Received: Approximately $9.3 million paid in cash by PIPE investors.
- Debt Settlement: Approximately $3.6 million of the purchase price was used to offset amounts owed to investors, primarily Veru Inc.
- Securities Issued: 16,099 shares of Series D Convertible Preferred Stock (par value $0.00001) and warrants to purchase 4,362,827 shares of Common Stock.
- Conversion Terms: Series D Preferred Stock has a stated value of $1,000 per share and a conversion price of $3.6896 per share, subject to anti-dilution adjustments and a floor price of $0.7379.
- Termination Payment: The Company paid $302,343.55 to Ocuvex Therapeutics, Inc. to terminate the Merger Agreement.
Material Changes and Transactions
1. PIPE Financing and Series D Preferred Stock
The Company entered into a Securities Purchase Agreement with eleven institutional investors. The Series D Preferred Stock ranks senior to Common Stock and pari passu with Series C Preferred Stock. Key features include:
- Dividends: Discretionary dividends may be declared. In the event of a "Triggering Event" (e.g., failure to file registration statements, bankruptcy, or default on debt), default dividends accrue at 15.0% per annum.
- Conversion Rights: Holders may convert at the option of the holder. Triggering Events allow for conversion at a lower "Alternate Conversion Price" based on the lowest VWAP of the Common Stock.
- Redemption: The Company has the right to redeem shares at a 25% premium on the greater of the conversion amount or the market value.
- Registration Rights: The Company agreed to file a registration statement within 45 days of closing, with effectiveness required within 120 days.
2. Veru Inc. Settlement
The Company settled approximately $8.8 million in outstanding obligations to Veru Inc. (related to the 2023 asset purchase of the ENTADFI business). The settlement terms included:
- Cash payment of approximately $6.3 million (including accrued interest).
- Issuance of 3,125 shares of Series D Preferred Stock.
- Issuance of 846,975 Warrants.
- Full release of all claims by Veru Inc. as of September 24, 2025.
3. Termination of Merger Agreement
The Company terminated the Agreement and Plan of Merger with Ocuvex Therapeutics, Inc., effective September 24, 2025. The termination was triggered after the Company received a "Parent Superior Proposal" and the Board made an adverse recommendation change. The Company paid the required termination fee of $302,343.55.
Guidance, Risks, and Contingencies
- Triggering Events: The Series D Preferred Stock contains extensive "Triggering Event" provisions that could accelerate conversion rights or increase dividend accruals. These include failures to maintain registration statements, suspension of trading, defaults on indebtedness exceeding $500,000, or the occurrence of a Material Adverse Effect.
- Dilution Risk: The conversion price and warrant exercise price are subject to downward adjustments for dilutive issuances, variable price securities, and stock combinations if the market price falls below the conversion price.
- Liquidity: The filing does not provide specific liquidity metrics (e.g., cash on hand) outside of the $9.3 million cash proceeds from the PIPE financing.
- Ownership Limitations: A "PIPE Blocker" limits beneficial ownership to 4.99% (adjustable to 9.99%) upon conversion or exercise, which may restrict the ability of investors to liquidate positions immediately.
Investor Verification Checklist
- Verify the effective date of the registration statement for the PIPE securities (required within 120 days of closing).
- Confirm the current cash balance and burn rate post-settlement to assess runway.
- Review the specific terms of the "Parent Superior Proposal" that led to the merger termination, as this may indicate future M&A activity.
- Monitor the Company's compliance with the "Triggering Event" covenants, particularly regarding the maintenance of registration statements and debt obligations.
- Check for any subsequent dilutive issuances that could lower the $3.6896 conversion price.